Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Manshenkang
- Development stage
- Preclinical
- Modality
- Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Manshenkang (MSKG) is a traditional Chinese medicinal (TCM) formula used for the treatment of chronic renal failure and renal fibrosis. It is a multi-component herbal preparation comprising eight botanical and natural ingredients: *Rheum tanguticum*, *Salvia miltiorrhiza*, *Citrus × aurantium*, *Codonopsis pilosula*, *Polygonatum cyrtonema*, *Smilax glabra*, *Ostrea rivularis*, and *Glycyrrhiza uralensis*. Research indicates that Manshenkang exerts its therapeutic effects by regulating the PDE4b/cAMP/Epac1 signaling pathway. Specifically, it inhibits the expression of phosphodiesterase 4b (PDE4b), which leads to increased levels of cyclic adenosine monophosphate (cAMP) and activation of the exchange protein directly activated by cAMP 1 (Epac1). This mechanism helps alleviate renal fibrosis, reduce serum creatinine and urea nitrogen levels, and improve creatinine clearance and renal blood flow in animal models of chronic renal failure.
- Brand names
- Manshenkang
- Other names
- Manshenkang granulesMSKG
02
Targets
PDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)
Beyond the preview
Go deeper on Manshenkang.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Manshenkang.